A Phase 3 interventional study of Genotropin and Genotropin in Idiopathic Short Stature, sponsored by Pfizer. Completed at 43 sites in United States. Open to participants aged 3 Years to 10 Years. Per ClinicalTrials.gov, last updated 2016-04-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to explore treatment efficiency over four years of two formula-based dose regimens (sub-arms) compared to standard treatment
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Standard daily HGH treatment
Drug: Genotropin
Formula-based dose regimen
Drug: Genotropin
Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
Absolute On-target Difference (AOTD) at 24 Months
This was defined as an absolute difference between the 24-month height standard deviation score (SDS) and targeted 24-month height SDS (10th percentile (%), or -1.3 SDS). SDS indicates how similar the participant was to the reference population. These were calculated using 2000 Center for the Disease Control (CDC) growth reference tables (by age and gender).
Time frame: 2 years
Variability of Height SDS at 24 Months
The continuous endpoint of variability of height SDS at 24 months was defined as the SD of the 24 month height SDS.
Time frame: 2 years
Time Cost (Months Until >= -2 SDS)
Time cost was defined as the number of months needed until height SDS was within the normal limit (ie, \>= -2SDS).
Time frame: 2 years
Computed Cost of Height Gain at 48 Months
The computed cost of height gain was defined as the amount of drug used relative to the observed height-gain, in terms of mg/cm, this was calculated at Month 48.
Time frame: 4 years
Estimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months
The estimated cost of long-term height gain until FAH was calculated.
Time frame: 4 years
Change From Baseline in Height SDS at 48 Months.
Change in height SDS was measured at 48 months.
Time frame: 4 years
This was a 4-year, open-label, randomized study conducted at 40 centers across United States of America (USA). The first 2-years of the study constituted core phase and the last 2 years constituted the maintenance phase.
| Milestone | Standard Dose Arm | Individualized Dose Arm |
|---|---|---|
| Started | 114 | 202 |
| Completed | 88 | 156 |
| Not completed | 26 | 46 |
| Withdrew: Withdrawal by subject | 17 | 17 |
| Withdrew: Lost to follow-up | 4 | 9 |
| Withdrew: Other | 3 | 5 |
| Withdrew: Protocol violation | 0 | 6 |
| Withdrew: Adverse event | 1 | 5 |
| Withdrew: Insufficient clinical response | 1 | 4 |
This was defined as an absolute difference between the 24-month height standard deviation score (SDS) and targeted 24-month height SDS (10th percentile (%), or -1.3 SDS). SDS indicates how similar the participant was to the reference population. These were calculated using 2000 Center for the Disease Control (CDC) growth reference tables (by age and gender).
| Standard Deviation Score (SDS) | Standard Dose Arm | Individualized Dose Arm |
|---|---|---|
| Absolute On-target Difference (AOTD) at 24 Months | 0.603 ± 0.2948 | 0.625 ± 0.3003 |
The continuous endpoint of variability of height SDS at 24 months was defined as the SD of the 24 month height SDS.
| Standard Deviation Score (SDS) | Standard Dose Arm | Individualized Dose Arm |
|---|---|---|
| Change from baseline at 24 months (n=101,184) | 1.12 ± 0.408 | 1.11 ± 0.518 |
| Change from baseline at 24 months LOCF (n=114,202) | 1.03 ± 0.475 | 1.04 ± 0.544 |
Time cost was defined as the number of months needed until height SDS was within the normal limit (ie, \>= -2SDS).
| Months | Standard Dose Arm | Individualized Dose Arm |
|---|---|---|
| Time Cost (Months Until >= -2 SDS) | 12.00 (8.00 to 12.00) | 12.00 (8.00 to 12.00) |
The computed cost of height gain was defined as the amount of drug used relative to the observed height-gain, in terms of mg/cm, this was calculated at Month 48.
| mg/cm | Standard Dose Arm | Individualized Dose Arm Overall | Individualized Dose Arm 0.18 mg/kg/Week | Individualized Dose Arm 0.24 mg/kg/Week |
|---|---|---|---|---|
| Computed Cost of Height Gain at 48 Months | 72.77 ± 17.914 | 67.30 ± 24.382 | 63.07 ± 21.656 | 69.62 ± 21.903 |
The estimated cost of long-term height gain until FAH was calculated.
| mg/cm | Standard Dose Arm | Individualized Dose Arm Overall | Individualized Dose Arm 0.18 mg/kg/Week | Individualized Dose Arm 0.24/mg/kg/Week |
|---|---|---|---|---|
| Estimated Cost of Height Gain Estimated Until Full Adult Height (FAH) at 48 Months | 127.99 ± 29.708 | 91.34 ± 31.854 | 80.06 ± 21.000 | 92.24 ± 25.213 |
Change in height SDS was measured at 48 months.
| Standard Deviation Score (SDS) | Standard Dose Arm | Individualized Dose Arm Overall | Individualized Dose Arm 0.18 mg/kg/Week | Individualized Dose Arm 0.24 mg/kg/Week |
|---|---|---|---|---|
| Change From Baseline in Height SDS at 48 Months. | 1.33 ± 0.717 | 1.24 ± 0.668 | 1.33 ± 0.637 | 1.34 ± 0.633 |
Collected over 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard Dose Arm | — | 13/118 (11%) | 103/118 (87.3%) |
| Individualized Dose Arm | — | 7/198 (3.5%) | 165/198 (83.3%) |
| Event | Standard Dose Arm | Individualized Dose Arm |
|---|---|---|
| PneumoniaInfections and infestations | 2/118 | 0/198 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/118 | 0/198 |
| Arnold-chiari malformationCongenital, familial and genetic disorders | 1/118 | 0/198 |
| Abdominal painGastrointestinal disorders | 1/118 | 0/198 |
| Intestinal obstructionGastrointestinal disorders | 1/118 | 0/198 |
| AppendicitisInfections and infestations | 1/118 | 1/198 |
| Postoperative wound infectionInfections and infestations | 1/118 | 0/198 |
| AccidentInjury, poisoning and procedural complications | 1/118 | 0/198 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 1/118 | 0/198 |
| Facial bones fractureInjury, poisoning and procedural complications | 1/118 | 0/198 |
| Event | Standard Dose Arm | Individualized Dose Arm |
|---|---|---|
| HeadacheNervous system disorders | 33/118 | 59/198 |
| Upper respiratory tract infectionInfections and infestations | 28/118 | 45/198 |
| Pharyngitis streptococcalInfections and infestations | 15/118 | 30/198 |
| InfluenzaInfections and infestations | 16/118 | 22/198 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/118 | 26/198 |
| VomitingGastrointestinal disorders | 15/118 | 21/198 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/118 | 24/198 |
| NasopharyngitisInfections and infestations | 8/118 | 25/198 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/118 | 17/198 |
| Otitis mediaInfections and infestations | 11/118 | 23/198 |
| Age, Continuous(Years) | Standard Dose Arm | Individualized Dose Arm | Total |
|---|---|---|---|
| Mean | 8.3 ± 2.1 | 8.4 ± 2.3 | 8.4 ± 2.2 |
| Age, Customized(Participants) | Standard Dose Arm | Individualized Dose Arm | Total |
|---|---|---|---|
| <= 7 years | 37 | 70 | 107 |
| >=7 years | 77 | 132 | 209 |
| Sex: Female, Male(Participants) | Standard Dose Arm | Individualized Dose Arm | Total |
|---|---|---|---|
| Female | 31 | 58 | 89 |
| Male | 83 | 144 | 227 |
The record gives a start of Dec 2006, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2013, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone